Effects of Probiotics and Prebiotics on Frailty and Ageing: A Narrative Review.

IF 3.2 Q2 Pharmacology, Toxicology and Pharmaceutics

Current clinical pharmacology Pub Date : 2019-11-20 DOI:10.2174/1574884714666191120124548

Kulapong Jayanama, O. Theou

{"title":"Effects of Probiotics and Prebiotics on Frailty and Ageing: A Narrative Review.","authors":"Kulapong Jayanama, O. Theou","doi":"10.2174/1574884714666191120124548","DOIUrl":null,"url":null,"abstract":"Globally, the population over the age of 60 is growing fast, but people age in different ways. Frailty, shown by the accumulation of age-related deficits, is a state of increased vulnerability to adverse outcomes among people of the same chronological age. Ageing results in a decline in diversity and homeostasis of microbiomes, and gut flora changes are related to health deficit accumulation and adverse health outcomes. In older people, health deficits including inappropriate intake, sarcopenia, physical inactivity, polypharmacy, and social vulnerability are factors associated with gut dysbiosis. The use of probiotics and prebiotics is a cost-effective and widely available intervention. Intake of probiotics and prebiotics may improve the homeostasis of gut microflora and prevent frailty and unhealthy aging. However, health effects vary among probiotics and prebiotics and among individual populations. This narrative review summarizes recent evidence about the relationship of prebiotic and probiotic consumption with health outcomes in older people.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666191120124548","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574884714666191120124548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 19

Abstract

Globally, the population over the age of 60 is growing fast, but people age in different ways. Frailty, shown by the accumulation of age-related deficits, is a state of increased vulnerability to adverse outcomes among people of the same chronological age. Ageing results in a decline in diversity and homeostasis of microbiomes, and gut flora changes are related to health deficit accumulation and adverse health outcomes. In older people, health deficits including inappropriate intake, sarcopenia, physical inactivity, polypharmacy, and social vulnerability are factors associated with gut dysbiosis. The use of probiotics and prebiotics is a cost-effective and widely available intervention. Intake of probiotics and prebiotics may improve the homeostasis of gut microflora and prevent frailty and unhealthy aging. However, health effects vary among probiotics and prebiotics and among individual populations. This narrative review summarizes recent evidence about the relationship of prebiotic and probiotic consumption with health outcomes in older people.

查看原文本刊更多论文

益生菌和益生素对虚弱和衰老的影响：叙述性综述。

在全球范围内，60岁以上的人口正在快速增长，但人们的衰老方式各不相同。衰弱，表现为与年龄相关的缺陷的积累，是一种对相同实际年龄的人的不利结果更容易受到伤害的状态。衰老导致微生物群多样性和动态平衡的下降，肠道菌群的变化与健康赤字积累和不良健康结果有关。在老年人中，健康缺陷包括不适当的摄入、肌肉减少症、缺乏身体活动、多种药物和社会脆弱性是与肠道生态失调相关的因素。使用益生菌和益生元是一种具有成本效益和广泛可用的干预措施。摄入益生菌和益生元可以改善肠道菌群的动态平衡，防止虚弱和不健康的衰老。然而，益生菌和益生元对健康的影响因人群而异。这篇叙述性综述总结了最近关于益生元和益生菌消费与老年人健康结果关系的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current clinical pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

3.60

自引率

0.00%

发文量

期刊介绍： Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.